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outcome. “Understanding the condition/complications” and 
“attending medical appointments” were seen as having rel-
atively higher priority for endocrine TC. Barriers related 
to lack of inancial support and low institutional priority. 
Involving key stakeholders facilitated implementation. 
Having a dedicated nurse was noted as an opportunity 
for improving TC. CONCLUSIONS: Implementation of 
structured TC has been piecemeal and most practices 
do not fully utilize recommended best practices (‘Got 
Transition’). Few practices formally collect outcome data. 
The major perceived barrier to implementing TC is inan-
cial. Practices incorporating nurses value discipline-speciic 
contributions. These pilot data point to a role for nursing in 
providing comprehensive, high quality, comprehensive care 
for AYAs with chronic endocrine conditions.
Diabetes Mellitus and Glucose 
Metabolism
IMPACTS OF METABOLISM ON CLINICAL 
CHALLENGES
Lower Serum Myostatin Levels Are Associated with 
Higher Insulin Sensitivity in Adults with Overweight/
Obesity
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1Massachusetts General Hospital Neuroendocrine Unit/Harvard 
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In preclinical models, inhibition of the myokine myostatin 
prevents or improves insulin resistance (IR). However, 
studies investigating the association between serum 
myostatin levels and IR in humans are discrepant, per-
haps in part because myostatin immunoassays lack speci-
icity and sensitivity. New sensitive and speciic myostatin 
LC-MS/MS assays make it possible to determine if higher 
serum myostatin levels are independently associated with 
greater IR in adults with overweight/obesity. If true, ther-
apeutic manipulation of myostatin pathways may be a 
potential therapeutic target to prevent or treat type 2 dia-
betes (T2DM) in this high-risk population, in which current 
strategies, e.g. weight loss, are dificult to implement and 
maintain.
We studied 75 adults (53% women), 20–65 yo, BMI 
≥25  kg/m2 and generally healthy without T2DM. Serum 
myostatin levels (1° independent variable) were measured 
by LC-MS/MS (Brigham Research Assay Core, Boston, 
MA), with no cross-reactivity with growth differentiation 
factor 11 (GDF11), activins or transforming growth factor 
beta (TGF-β), sensitivity of 0.5  ng/mL and intra- and 
inter-assay coeficient of variation of 10 and 12%. Insulin 
sensitivity (IS) (1° dependent variable) was estimated by 
QUICKI, appendicular lean mass (ALM) by DXA, vis-
ceral adipose tissue (VAT) by CT and intrahepatic (IHL) 
and intramyocellular lipids (IMCL) by MR spectroscopy. 
Models were run sex- combined and stratiied given sex 
differences in muscle mass.
Mean age was 47.9±12.2 years and BMI was 33.2±5.7 kg/
m2 (mean±SD). Compared to men, women had lower 
mean ALM (20.9±3.3 vs 29.2±3.3 kg, p<0.0001) and serum 
myostatin levels (7.28±1.87 vs 8.28±1.89  ng/mL, p=0.02) 
and similar mean IS (0.16±0.02 vs 0.15±0.02, p=0.13). 
Lower serum myostatin levels were associated with higher 
IS in the whole group (R=-0.32, p=0.008) and in women 
(R=-0.41, p=0.02)—both remained signiicant after con-
trolling for ALM—but not in men (R=-0.16, p=0.36). In a 
multivariate model including VAT, IHL, IMCL and ALM, 
lower serum myostatin levels were associated with higher 
IS in the whole group (B
1
= -0.37, p=0.003), in women (B
1
= 
-0.43, p=0.02) and in men (B
1
= -0.37, p=0.05). In a step-
wise regression model including VAT, IHL, IMCL and ALM, 
VAT explained 18%, IHL explained 10% and myostatin 
explained 8% of the variability in IS in the whole group; in 
women, myostatin explained 18% and IHL explained 12% 
of the variability; in men, VAT explained 26% of the vari-
ability and myostatin was not a signiicant determinant.
In conclusion, lower serum myostatin levels were associ-
ated with greater IS in adults with overweight/obesity, 
independent of muscle and adipose depots known to be 
associated with T2DM risk. Future studies should inves-
tigate potential sex differences in the association between 
myostatin and IS. Therapeutic manipulation of myostatin 
pathways may be a potential therapeutic target to prevent 
or treat T2DM.
Bone and Mineral Metabolism
PARATHYROID HORMONE TRANSLATIONAL AND 
CLINICAL ASPECTS
Bioactivity of Long Acting PTH Fusion Molecules 
Tested in a Novel Non-Surgical Animal Model of 
Hypoparathyroidism
Ian R. Wilkinson, PhD1, Narjes Ramezani-Pour, Bsc2, 
Sayyed Hamid Zarkesh Esfahani, PhD2, Richard Eastell, 
MBChB, MD3, Richard John M Ross, MBBS,FRCP,MD3.
1Shefield University, Shefield, United Kingdom, 2Department 
of Cell and Molecular Biology & Microbiology, University Of 
Isfahan, Isfahan, Iran, Islamic Republic of, 3Univ of Shefield, 
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SAT-408
Introduction: There is an unmet need for the development 
of long-acting PTH molecules to treat patients with hypo-
parathyroidism. We have established a novel non-surgical 
rodent model of hypoparathyroidism using oral Cinacalcet-
HCl to test long acting analogues of PTH. Here we have 
tested the pharmacodynamics properties of two long acting 
PTH fusion molecules.
Methods: PTH fusion molecules tested: Fusion-1 is PTH 
(1–34) linked to GHBP (residues 1–238), and Fusion-2 is a 
Hybrid PTH-PTHrP (1) linked to GHBP (residues 1–238). 
For in vivo studies, normal male wistar rats were gavaged 
with 30 mg/kg Cinacalcet-HCl, immediately followed by a 
subcutaneous dose of PTH Fusion at 20 nmol/kg. Control 
animals received PTH (1–34) and vehicle only. Serum 
samples were taken and analysed for ionised calcium (iCa).
Results: Oral administration of Cinacalcet-HCl caused a 
reduction in iCa that was signiicantly different from vehicle 
controls at 2 to 24hrs post dose (ANOVA P < 0.0001). PTH 
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1–34 maintained iCa levels for 2 hours after administration 
above that of Cinacalcet-HCl (AUC±SD (mmol/L).hr from 
baseline, 0.076 ±0.047 and 0.168±0.0874, t-test P=0.0289) 
but then levels fell and recovered as for Cinacalcet-HCl 
alone. Subcutaneous doses of both fusions were able to ab-
rogate the effects of Cinacalcet-HCl from 4hrs post dose 
onwards giving a prolonged response, with iCa levels 
quicker to return to baseline levels at 48hrs compared to 
Cinacalcet-HCl. The AUC±SD (mmol/L).hr from baseline 
for iCa over 72 hours was 3.93±1.4 for Fusion-1, 5.0±2.7 
for Fusion-2 & 10±2.8 for Cinacaclet-HCl and were signii-
cantly reduced for both fusions compared to Cinacalcet-HCl 
alone (t-test P = 0.0028 & P = 0.019, respectively) and not 
signiicantly different from vehicle only.
Conclusions: Cinacalcet-HCl behaved as expected in 
terms of iCa lowering (2). PTH maintained iCa but only for 
2 hours. Both PTH fusion molecules showed a delayed and 
prolonged response and reduced the impact of Cinacalcet-
HCl induced low iCa levels from 4hrs to 24hrs. These data 
provide proof of concept for long acting biological activity of 
these novel PTH fusion proteins.
References:
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Pediatric Endocrinology
UNDERSTANDING AND TREATING PEDIATRIC 
GROWTH DISORDERS
Diagnosis of Severe GH Deiciency in Newborns: New 
Reference Range for the Preterm and Conirmation of 
the GH Cut-Off
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Introduction
Inborn severe GHD is caused by rare disorders of pitui-
tary morphogenesis or function and frequently associated 
with additional pituitary hormone deiciencies. Affected 
newborns commonly present with recurrent hypoglycemia; 
therefore early diagnosis and therapy is warranted. The 
GH content of the newborn screening card is a reliable in-
dicator of severe neonatal GHD. Here, we studied the GH 
content in screening cards and the history of 25 newborns 
with severe GHD. In addition, we determined the refer-
ence range of the GH content in screening cards from 282 
healthy preterm newborns.
Patients and Methods
Since 2010, a total of 110 screening cards from hospitalized 
ill newborns were sent to our laboratory for measuring GH 
content. Using a questionnaire we obtained relevant clin-
ical information from senders in 61 cases. Severe GHD was 
deined by the presence of recurrent neonatal hypoglycemia 
with either a signiicant cerebral MRI morphology or two 
additional pituitary hormone deiciencies. In addition, the 
GH content of screening cards from 282 healthy newborns 
born preterm with a gestational age at birth from 34.0 to 
37.9 weeks was prospectively analyzed. The GH concentra-
tion of the eluate from the screening card was measured by 
a highly sensitive ELISA (Mediagnost, Germany); the GH 
serum concentration was calculated.
Results
In 25 patients, the deinition of severe GHD of the newborn 
was fulilled; based on recurrent hypoglycemia in combi-
nation with ectopia of the neurohypophysis in 17, septum 
pellucidum agenesis plus opticus hypoplasia in two, severely 
hypoplastic pituitary gland in two, and combined TSH and 
ACTH deiciency with no cMRI indings in four newborns. 
Five newborns with severe GHD were preterm. The median 
GH concentration of the term newborns with severe GHD 
(n=20) was 3.9 µg/l (range; 1.1 to 11.8). This was signii-
cantly below the previously reported reference data from 
healthy term newborns (n=269) (median 16.4 µg/l; 95% ref-
erence range 7.0 to 39.4) (p<0.001). Using ROC plot anal-
ysis a GH serum concentration of 7.0  µg/l was identiied 
as cut-off with the highest accuracy (90.0% sensitivity and 
98.7% speciicity). The median GH concentration of the 5 
preterm newborns with severe GHD was 7.7  µg/l (range; 
2.1 to 9.9). The newly determined 95% reference range for 
healthy newborns born preterm with a gestational age from 
34.0 to 37.9 weeks (n=282) spanned from 7.9 to 41.1 µg/l 
with a median of 20.3 µg/l.
Conclusions
A GH content below 7.0  ng/ml in the newborn screening 
card identiied severe GHD with 90% sensitivity and 98.7% 
speciicity. In preterm newborns, the lower limit of the 
95% reference interval was by 0.9 µg/l higher than in term 
newborns. The newborn screening card is a valuable source 
for the diagnosis of GH deiciency in newborns and young 
infants.
Neuroendocrinology and Pituitary
HYPOTHALAMIC-PITUITARY DEVELOPMENT 
AND FUNCTION
Osteocalcin and Exercise Improve Mood and 
Cognition in Female Mice with High-Fat Diet Induced 
Type 2 Diabetes.
Jesse Rentz, BSc.H, Jordan Winberg, BSc.H, Walter Swardfager, 
PhD, Jane Mitchell, PhD.
University of Toronto, Toronto, ON, Canada.
SAT-293
The skeleton has been characterized as an endocrine organ, 
demonstrating a capacity to modulate cognition, mood and 
energy homeostasis (1,2). These endocrine actions of the 
skeleton have been attributed to the osteoblast-derived 
peptide osteocalcin. In mice, uncarboxylated osteocalcin 
(ucOCN) decreased the acquisition of type 2 diabetes mel-
litus (T2DM) and ameliorated depressive- and anxiety-like 
behaviours (1,2). Clinically, T2DM patients present with 
reduced serum osteocalcin levels and approximately 1 
in 4 also suffer from co-morbid depression (3,4). The cog-
nitive and metabolic beneits of ucOCN are similar to the 
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